Paediatric Cholestatic Liver Disease: Diagnosis, Assessment of Disease Progression and Mechanisms of Fibrogenesis

Overview

Journal World J Gastrointest Pathophysiol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2011 May 25

PMID 21607144

Citations 11

Authors

Tamara N Pereira

Meagan J Walsh

Peter J Lewindon

Grant A Ramm

Affiliations

Soon will be listed here.

Abstract

Cholestatic liver disease causes significant morbidity and mortality in children. The diagnosis and management of these diseases can be complicated by an inability to detect early stages of fibrosis and a lack of adequate interventional therapy. There is no single gold standard test that accurately reflects the presence of liver disease, or that can be used to monitor fibrosis progression, particularly in conditions such as cystic fibrosis. This has lead to controversy over how suspected liver disease in children is detected and diagnosed. This review discusses the challenges in using commonly available methods to diagnose hepatic fibrosis and monitor disease progression in children with cholestatic liver disease. In addition, the review examines the mechanisms hypothesised to be involved in the development of hepatic fibrogenesis in paediatric cholestatic liver injury which may ultimately aid in identifying new modalities to assist in both disease detection and therapeutic intervention.

Citing Articles

Efficacy and Safety of Ileal Bile Acid Transport Inhibitors in Inherited Cholestatic Liver Disorders: A Meta-analysis of Randomized Controlled Trials.

Imran M, Elsnhory A, Ibrahim A, Elnaggar M, Tariq M, Mehmood A J Clin Exp Hepatol. 2025; 15(3):102462.

PMID: 39802553 PMC: 11720443. DOI: 10.1016/j.jceh.2024.102462.

Evaluation of Hepatic Shear Wave Elastography to Assess Liver Fibrosis in Biliary Atresia Patients and Its Correlation with Liver Histology and Surgical Outcomes: A Prospective Observational Study.

Ahmad M, Solanki S, Kanojia R, Bhatia A, Lal S, Saxena A Indian J Radiol Imaging. 2024; 34(4):646-652.

PMID: 39318570 PMC: 11419772. DOI: 10.1055/s-0044-1787668.

Age-specific reference intervals for liver function tests in healthy neonates, infants, and young children in Iran.

Badakhshan S, Ghazizadeh H, Mohammadi-Bajgiran M, Esmaily H, Khorasani M, Bohn M J Clin Lab Anal. 2023; 37(23-24):e24995.

PMID: 38087776 PMC: 10756939. DOI: 10.1002/jcla.24995.

Liver disease in cystic fibrosis patients in a tertiary care center in Saudi Arabia.

Banjar H, Abdulaziz N, Khader J, Ghomraoui F, Alansari A, Al-Hoshan A Int J Pediatr Adolesc Med. 2022; 9(2):78-82.

PMID: 35663788 PMC: 9152554. DOI: 10.1016/j.ijpam.2021.06.002.

Diagnostic accuracy of two-dimensional shear wave elastography in detecting hepatic fibrosis in children with autoimmune hepatitis, biliary atresia and other chronic liver diseases.

Galina P, Alexopoulou E, Mentessidou A, Mirilas P, Zellos A, Lykopoulou L Pediatr Radiol. 2021; 51(8):1358-1368.

PMID: 33755748 DOI: 10.1007/s00247-020-04959-9.

References

Lan R, Cheng C, Lian Z, Tsuneyama K, Yang G, Moritoki Y . Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology. 2006; 43(4):729-37. DOI: 10.1002/hep.21123. View

Lindblad A, Glaumann H, Strandvik B . Natural history of liver disease in cystic fibrosis. Hepatology. 1999; 30(5):1151-8. DOI: 10.1002/hep.510300527. View

Nakano M, Lieber C . Ultrastructure of initial stages of perivenular fibrosis in alcohol-fed baboons. Am J Pathol. 1982; 106(2):145-55. PMC: 1916180. View

Pockros P, Schiff E, Shiffman M, McHutchison J, Gish R, Afdhal N . Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007; 46(2):324-9. DOI: 10.1002/hep.21664. View

FitzSimmons S . The changing epidemiology of cystic fibrosis. J Pediatr. 1993; 122(1):1-9. DOI: 10.1016/s0022-3476(05)83478-x. View

Colombo C, Crosignani A, Battezzati P . Liver involvement in cystic fibrosis. J Hepatol. 1999; 31(5):946-54. DOI: 10.1016/s0168-8278(99)80299-2. View

Lu T, Makishima M, REPA J, Schoonjans K, Kerr T, Auwerx J . Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell. 2000; 6(3):507-15. DOI: 10.1016/s1097-2765(00)00050-2. View

Ramadori G, Saile B . Portal tract fibrogenesis in the liver. Lab Invest. 2003; 84(2):153-9. DOI: 10.1038/labinvest.3700030. View

Iredale J, Murphy G, Hembry R, Friedman S, Arthur M . Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J Clin Invest. 1992; 90(1):282-7. PMC: 443094. DOI: 10.1172/JCI115850. View

10.

Langer D, Das A, Semela D, Kang-Decker N, Hendrickson H, Bronk S . Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. Hepatology. 2008; 47(6):1983-93. PMC: 2562502. DOI: 10.1002/hep.22285. View

11.

Sokol R, Durie P . Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr. 1999; 28 Suppl 1:S1-13. DOI: 10.1097/00005176-199900001-00001. View

12.

Fabris L, Cadamuro M, Guido M, Spirli C, Fiorotto R, Colledan M . Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. Am J Pathol. 2007; 171(2):641-53. PMC: 1934520. DOI: 10.2353/ajpath.2007.070073. View

13.

Kruglov E, Nathanson R, Nguyen T, Dranoff J . Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts. Am J Physiol Gastrointest Liver Physiol. 2005; 290(4):G765-71. DOI: 10.1152/ajpgi.00308.2005. View

14.

Pereira T, Lewindon P, Smith J, Murphy T, Lincoln D, Shepherd R . Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease. J Hepatol. 2004; 41(4):576-83. DOI: 10.1016/j.jhep.2004.06.032. View

15.

Richardson M, Jonsson J, Powell E, Brunt E, Neuschwander-Tetri B, Bhathal P . Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology. 2007; 133(1):80-90. DOI: 10.1053/j.gastro.2007.05.012. View

16.

Clouston A, Jonsson J, Powell E . Hepatic progenitor cell-mediated regeneration and fibrosis: chicken or egg?. Hepatology. 2009; 49(5):1424-6. DOI: 10.1002/hep.22893. View

17.

Hofmann A . Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol Suppl. 1994; 204:1-15. DOI: 10.3109/00365529409103618. View

18.

Kallis Y, Forbes S . The bone marrow and liver fibrosis: friend or foe?. Gastroenterology. 2009; 137(4):1218-21. DOI: 10.1053/j.gastro.2009.08.026. View

19.

Tiggelman A, Boers W, Linthorst C, Brand H, Sala M, Chamuleau R . Interleukin-6 production by human liver (myo)fibroblasts in culture. Evidence for a regulatory role of LPS, IL-1 beta and TNF alpha. J Hepatol. 1995; 23(3):295-306. View

20.

Watanabe A, Hashmi A, Gomes D, Town T, Badou A, Flavell R . Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology. 2007; 46(5):1509-18. DOI: 10.1002/hep.21867. View